SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy

BACKGROUND: Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been documented, raising public health concerns. SARS-CoV-2 reinfections were assessed in a cohort of antibody-positive persons in Qatar. METHODS: All SARS-CoV-2 antibody-positive persons from April 16...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:EClinicalMedicine
Auteurs principaux: Abu-Raddad, Laith J., Chemaitelly, Hiam, Coyle, Peter, Malek, Joel A., Ahmed, Ayeda A., Mohamoud, Yasmin A., Younuskunju, Shameem, Ayoub, Houssein H., Al Kanaani, Zaina, Al Kuwari, Einas, Butt, Adeel A., Jeremijenko, Andrew, Kaleeckal, Anvar Hassan, Latif, Ali Nizar, Shaik, Riyazuddin Mohammad, Abdul Rahim, Hanan F., Nasrallah, Gheyath K., Yassine, Hadi M., Al Kuwari, Mohamed Ghaith, Al Romaihi, Hamad Eid, Al-Thani, Mohamed H., Al Khal, Abdullatif, Bertollini, Roberto
Format: Artigo
Langue:Inglês
Publié: Elsevier 2021
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8079668/
https://ncbi.nlm.nih.gov/pubmed/33937733
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2021.100861
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires